Of note, we could not detect any expression in the brain (results not shown)

Of note, we could not detect any expression in the brain (results not shown). remodellingin vivo. Keywords:exercise, fibre type switch, muscle mass remodelling, myocyte enhancer factor 2 (MEF2), myosin heavy chain (MHC), protein kinase D (PKD) == INTRODUCTION == Skeletal muscle mass is composed of a heterogenous populace of myofibres, which differ in their metabolic and contractile properties and are classified based on their expression of MHC (myosin heavy chain) genes. Type I fibres (slow-twitch fibres) express MHC type I, exert slow contraction, are oxidative and rich in mitochondria and myoglobin, and have a high resistance to fatigue, whereas fast-twitch or type II fibres express MHC type II, exert quick contraction, fatigue rapidly, and rely on glycolytic (type IIb and IId/x) or oxidative (type IIa) metabolism. Physiological signals such as exercise induce transmission transduction pathways that promote adaptive changes in the protein composition and cytoarchitecture of myofibres, thus transforming pre-existing type II fast-twitch fibres into type I slow-twitch fibres [1]. One important transcription factor involved in the regulation of myofibre remodelling is usually MEF2 (myocyte enhancer factor 2) [1,2]. There is substantial evidence that MEF2 is usually a key regulator of skeletal muscle mass development and myofibre remodelling. MEF2 is usually preferentially activated in slow oxidative fibres to support Ca2+-dependent signalling pathways that promote fibre type remodelling [2]. Moreover, skeletal muscle tissue of MEF2-knockout mice demonstrate a reduction in type I fibres. Conversely, expression of a constitutively active MEF2 protein increases the quantity of slow-twitch fibres in skeletal muscle mass and thus exercise endurance and muscle mass overall performance [3]. Transcriptional activity of MEF2 is usually inhibited by its direct interaction with users of the class IIa HDACs (histone deacetylases), which repress the INT-767 ability of MEF2 to bind INT-767 DNA [2]. Class IIa HDAC family members include HDAC4, HDAC5, HDAC7 and HDAC9. The activity of class IIa HDACs towards MEF2 is usually highly controlled by phosphorylation on conserved serine residues. Phosphorylation at these sites induces binding of HDACs to 14-3-3 proteins, thereby mediating unmasking and masking of nuclear export and nuclear localization sequences respectively. The phosphorylation-dependent conversation with 14-3-3 proteins results in the retention of class IIa HDACs in the cytoplasm, the release of MEF2 and thus derepression of downstream target genes [4]. For example, phosphorylation-dependent nuclear export of class IIa HDACs was exhibited for HDAC5 in cultured myoblasts upon initiation of the muscle mass differentiation programme [5]. In addition, HDAC4 and HDAC7 translocate from your nucleus to the cytoplasm in a signal-dependent manner in cultured adult skeletal muscle mass [6,7] and during MEF2-mediated differentiation of mouse myoblasts [8] respectively. Several serine/threonine kinases can phosphorylate class IIa HDACs at the 14-3-3-binding sites, including CaMK (Ca2+/calmodulin-dependent protein kinase) II [9,10], AMPK (AMP-activated protein kinase) [11], the AMPK family kinase Mark2 [12], and the salt-induced kinase Sik1 [13]. In an elegant screen, Chang and co-workers [12] recognized PKD (protein kinase D) as an additional class IIa HDAC kinase. The PKD family of serine/threonine kinases consists of three isoforms: PKD1, PKD2 and PKD3. Previous Rabbit polyclonal to ECHDC1 work has exhibited a functional interplay between PKD and HDACs in agonist-dependent cardiac hypertrophy. Vega and co-workers [14] have shown that PKD1 directly phosphorylates HDAC5 thereby promoting binding of 14-3-3 proteins and nuclear export. The ability of PKD to phosphorylate and inhibit HDAC5 correlates with pathological remodelling of the heart: expression of PKD1ca (constitutively INT-767 active PKD1) or excessive activation of PKD1 prospects to cardiac remodelling, heart failure and death [15]. Conversely, heart-specific deletion of PKD1 diminishes hypertrophy and pathological remodelling in response to pressure.